Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Feasibility and Effects of a Realistic Stressful Virtual Environment on Balance and Mobility in Healthy Adults: A Pilot Study

5 november 2026 bijgewerkt door: Vrije Universiteit Brussel

Does a Real-life Stressful Virtual Environment Change Balance and Mobility Performance? A Pilot Feasibility Study

The goal of this pilot clinical trial is to evaluate the feasibility of a new approach to assessing balance and mobility in everyday situations by performing established clinical tests in a stressful virtual reality environment. The study involves healthy adults aged 18 years and older with no self-reported neurological disorders or history of epilepsy.

The main questions it aims to answer are:

  1. Is it feasible to perform standard balance and mobility tests in a virtual reality environment simulating a busy train station?
  2. How does this virtual environment affect participants' balance and mobility test performance?
  3. How do participants experience the virtual environment, including their sense of being there and any discomfort or virtual reality sickness?

Researchers will compare each participant's performance with and without virtual reality to see if the virtual environment changes balance and mobility test results.

Participants will:

  • Spend a brief familiarisation period in the virtual environment before testing.
  • Complete the Mini-BESTest, which assesses balance through a series of tasks, with and without virtual reality.
  • Complete the Timed Up and Go test, which involves standing up from a chair, walking three meters, turning, returning, and sitting down, with and without virtual reality and with and without counting backwards by threes.
  • Complete the 10-Meter Walk Test at comfortable and fast walking speeds, with and without virtual reality.
  • Complete questionnaires after the final virtual reality exposure about their sense of being in the virtual environment and any symptoms of discomfort or sickness.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

11

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • healthy adults aged 18 years and older

Exclusion Criteria:

  • self-reported neurological disorders
  • history of epilepsy

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Balance and mobility assessment with and without virtual reality

All participants complete the Mini-BESTest, Timed Up and Go test, and 10-Meter Walk Test both without a virtual reality headset and while wearing a headset displaying a busy virtual train station. The Timed Up and Go test is performed with and without an additional cognitive task in each condition.

Participants wear a standalone virtual reality headset (Meta Quest 3) displaying a busy train-station environment while completing standard balance and mobility assessments. The environment includes moving pedestrians, animated displays, and recorded train-station sounds. Participants undergo a brief familiarisation period before testing.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of participants completing all planned assessments
Tijdsspanne: At the end of the single assessment session on Day 1, after completion or discontinuation of the planned assessments.

Proportion of participants who complete all planned assessments in both non-virtual reality (noVR) and virtual reality (VR) conditions. The predefined feasibility criterion is completion by at least 80% of participants.

At the end of the single assessment session on Day 1, after completion or discontinuation of the planned assessments.
Number of virtual reality-related technical issues
Tijdsspanne: From the start of virtual reality system setup to the end of the virtual reality assessments during the single assessment session on Day 1.

technical feasibility: assessed by the number and type of VR-related technical issues encountered

From the start of virtual reality system setup to the end of the virtual reality assessments during the single assessment session on Day 1.
Proportion of complete outcome measurements per test and condition
Tijdsspanne: Data recording during all planned tests in the virtual reality and non-virtual reality conditions within the single assessment session on Day 1.

data completeness: quantified as the proportion of complete outcome data per test and condition (criterion: ≥80% complete data)

Data recording during all planned tests in the virtual reality and non-virtual reality conditions within the single assessment session on Day 1.
Percentage increase in assessment time with virtual reality compared with no virtual reality
Tijdsspanne: From the start to the end of each assessment (mobility and balance assessments) in each condition (virtual reality and non-virtual reality) during the single assessment session on Day 1.

assessment burden: reflected by total assessment time, considered acceptable if VR assessments required no more than 20% additional time compared to noVR conditions

From the start to the end of each assessment (mobility and balance assessments) in each condition (virtual reality and non-virtual reality) during the single assessment session on Day 1.
Number of participants experiencing adverse events during assessment
Tijdsspanne: From the start of the assessment session until 15 minutes after its completion on Day 1, including both virtual reality and non-virtual reality assessments.

Number of participants experiencing at least one adverse event during the assessment session, including both virtual reality and non-virtual reality conditions, or within 15 minutes after its completion.

From the start of the assessment session until 15 minutes after its completion on Day 1, including both virtual reality and non-virtual reality assessments.
Virtual Reality Sickness Questionnaire scores (VRSQ)
Tijdsspanne: single session, Immediately after completion of the virtual reality session on Day 1.

The VRSQ is a modified version of the Simulator Sickness Questionnaire and consists of nine items assessing symptoms of VR-induced discomfort. These items are grouped into two subdomains: oculomotor discomfort (items 1-4) and disorientation (items 5-9). Each item is rated on a four-point Likert scale ranging from 0 ("not at all") to 3 ("severe"). Subscale scores are normalized and combined to yield a total VRSQ score, with higher scores indicating greater VR sickness.

single session, Immediately after completion of the virtual reality session on Day 1.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
iGroup Presence Questionnaire subscale scores
Tijdsspanne: single session, Immediately after completion of the virtual reality session on Day 1.

The IPQ assesses different dimensions of presence and consists of items grouped into four subscales: General Presence (GP), Spatial Presence (SP), Involvement (INV), and Experienced Realism (ER). Items are rated on a seven-point Likert scale ranging from 0 to 6, with higher scores indicating a stronger sense of presence within the virtual environment.

single session, Immediately after completion of the virtual reality session on Day 1.
Within-participant difference in Mini-BESTest total score between virtual reality and non-virtual reality conditions
Tijdsspanne: single session; During Mini-BESTest administration in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.

The Mini-Balance Evaluation Systems Test (Mini-BESTest) is a standardized clinical assessment of dynamic balance and a shortened version of the Balance Evaluation Systems Test (BESTest). It consists of 14 items covering four balance domains: anticipatory postural adjustments (items 1-3), reactive postural control (items 4-6), sensory orientation (items 7-9), and dynamic gait (items 10-14) (A.3). Each item is scored on a three-level ordinal scale (0-2), resulting in a maximum total score of 28 points, with higher scores indicating better balance performance. For items requiring bilateral assessment (items 3 and 6), the lower score was retained.

single session; During Mini-BESTest administration in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.
Within-participant difference in single-task and cognitive dual-task Timed Up and Go completion time between virtual reality and non-virtual reality conditions
Tijdsspanne: single session; During single-task and cognitive dual-task Timed Up and Go testing in both conditions (virtual reality and non-virtual reality) within the single assessment session on Day 1.

Participants are instructed to stand up from a chair, walk three meters at a safe and comfortable speed, cross a marked line on the floor, turn around, walk back to the chair, and sit down. The time required to complete the task was recorded in seconds. In addition to the standard single-task TUG, a cognitive dual-task version was administered. During the dual-task TUG, participants were asked to count backwards by threes from a randomly selected number between 20 and 100 while performing the motor task. Both single-task and dual-task TUG were performed under noVR and VR conditions, resulting in four TUG conditions in total.

single session; During single-task and cognitive dual-task Timed Up and Go testing in both conditions (virtual reality and non-virtual reality) within the single assessment session on Day 1.
Within-participant difference in comfortable walking speed between virtual reality and non-virtual reality conditions
Tijdsspanne: single session; During comfortable walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1

The 10-meter walk test was used to assess participants' walking speed. Participants started at the 0-meter (m) mark and walked to the 10 m mark. Timing was performed with a stop watch over the central 6 m, beginning 2 m after the start line and ending 2 m before the end line, to allow for acceleration and deceleration phases and to capture steady-state walking speed. Walking speed (m/s) was calculated by dividing the distance (6 m) by the recorded time (seconds). Two trials were performed at the participant's comfortable walking speed, followed by two trials at their fastest walking speed, according to standardized instructions.

For each speed condition, the two trials were averaged, and the resulting comfortable and fast gait speeds were documented in meters per second.

single session; During comfortable walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1
Within-participant difference in fast walking speed between virtual reality and non-virtual reality conditions
Tijdsspanne: single session; During fast walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.

The 10-meter walk test was used to assess participants' walking speed. Participants started at the 0-meter (m) mark and walked to the 10 m mark. Timing was performed with a stop watch over the central 6 m, beginning 2 m after the start line and ending 2 m before the end line, to allow for acceleration and deceleration phases and to capture steady-state walking speed. Walking speed (m/s) was calculated by dividing the distance (6 m) by the recorded time (seconds). Two trials were performed at the participant's comfortable walking speed, followed by two trials at their fastest walking speed, according to standardized instructions.

For each speed condition, the two trials were averaged, and the resulting comfortable and fast gait speeds were documented in meters per second.

single session; During fast walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Bart Jansen, PhD, ETRO, Vrije Universiteit Brussel

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

17 februari 2025

Primaire voltooiing (Werkelijk)

28 februari 2025

Studie voltooiing (Werkelijk)

28 februari 2025

Studieregistratiedata

Eerst ingediend

19 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

5 november 2026

Eerst geplaatst (Werkelijk)

12 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

5 november 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

De-identified individual participant data underlying the results reported in publications arising from this study will be made available by the corresponding author upon reasonable request following publication.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren